Physician profile
Wei Hou
NPI 1811104037
$8,017.54
in general payments reported to CMS, 2019-2025
32 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $310 · 2021: $1,055 · 2022: $1,099 · 2023: $689 · 2024: $1,511 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,394.68 | 2019-2025 | |
| Janssen Biotech, INC. | $1,597.52 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $501.52 | 2019-2025 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $488.93 | 2019-2025 | Linzess |
| Celgene Corporation | $335.01 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.42 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $315.63 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $248.57 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $232.72 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $217.18 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $145.73 | 2024-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $125.75 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $112.78 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $106.58 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $89.19 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $88.87 | 2024-2025 | Zenpep |
| Ucb, INC. | $81.33 | 2019-2020 | |
| Ardelyx, INC. | $80.89 | 2023-2024 | Ibsrela |
| Covidien LP | $76.50 | 2019 | |
| Lilly USA, LLC | $57.44 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $57.20 | 2023-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $50.89 | 2021-2023 | |
| Shionogi INC | $49.54 | 2019 | |
| Genzyme Corporation | $40.47 | 2019-2025 | |
| Amgen INC. | $40.30 | 2020-2021 | |
| Medtronic, INC. | $39.61 | 2024-2025 | Gi Genius, Pillcam |
| Novo Nordisk INC | $30.26 | 2025 | Wegovy |
| Blueprint Medicines Corporation | $24.57 | 2025 | Ayvakit |
| Shire North American Group INC | $17.38 | 2019 | |
| Boston Scientific Corporation | $15.27 | 2025 | Orca |
| Braintree Laboratories, INC. | $11.96 | 2022 | |
| Mallinckrodt Hospital Products INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Hou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.